AstraZeneca (<a>(AZN)</a>), AstraZeneca plc (<a>(GB:AZN)</a>), AstraZeneca (<a>(DE:ZEGA)</a>), Arcus Biosciences (<a>(RCUS)</a>), AstraZeneca plc US (<a>(AZNCF)</a>) announced an update on their ongoing clinical study.\n\nAstraZeneca and Arcus Biosciences are currently conducting a Phase III clinical study titled ‘A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy.’ The study aims to evaluate the efficacy and safety of combining durvalumab with domvanalimab compared to durvalumab with a placebo in treating Stage III unresectable non-small cell lung cancer (NSCLC).\n\nThe study tests two interventions: durvalumab, an immunotherapy drug, and domvanalimab, an anti-TIGIT antibody. These are administered via intravenous infusion every four weeks for up to 12 months, aiming to enhance the immune response against cancer cells.\n\nThis interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to determine the effectiveness of the drug combination.\n\nThe study began on February 18, 2022, and is currently recruiting participants. The primary completion date is projected for July 23, 2025, which is also the date of the last update. These timelines are crucial for stakeholders to track the study’s progress and anticipate results.\n\nThis study could significantly impact AstraZeneca and Arcus Biosciences’ stock performance, as positive outcomes may enhance their market positions in the oncology sector. Investors should monitor this study closely, considering the competitive landscape in cancer treatment.\n\nThe study is ongoing, with further details available on the ClinicalTrials portal.

AstraZeneca’s Promising Phase III Study on NSCLC Treatment: Key Insights for Investors

AstraZeneca and Arcus Biosciences are conducting a Phase III clinical trial to evaluate the efficacy of combining durvalumab and domvanalimab in treating Stage III unresectable non-small cell lung cancer (NSCLC). The study, which began in 2022 and is projected to complete in 2025, employs a randomized, double-blind design with quadruple masking to ensure unbiased results. Positive outcomes could impact the companies' stock performance in the oncology sector.